1 completed, 1 no longer available, 1 unknown, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Trametinib 2 MG: new trials by email Literature Review of Trametinib 2 MG trials Research Report on Trametinib 2 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) Dabrafenib 75 MG, Trametinib 2 MG - Thyroid Cancer | Phase 2 | Unknown | Olivia Newton-John Cancer Research Institute | 80 | 2022-07-14 | 2023-10-31 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG - Non Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2018-10-09 | 2025-05-16 |
| A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors Trametinib 0.5 mg, Trametinib 2 mg, ORTHO-NOVUM® tablet 1/35 - Cancer | Phase 1 | Withdrawn | GlaxoSmithKline | 2016-02-01 | 2016-01-26 | |
| Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib Trametinib 2 mg - Progressive Metastatic Castrate Resistant Prostate Cancer | No longer available | Jonsson Comprehensive Cancer Center | 2019-01-16 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Thyroid Neoplasms (1)
GlaxoSmithKline (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Olivia Newton-John Cancer Research Institute (1)
Australia (1) · United States (1)
Andrew M Scott, MD, FRACP (1) · Kathryn Arbour, MD (1) · Matthew Rettig, M.D. (1)